Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant

Gefapixant, a P2X3‐receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies between‐ and within‐participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Akshita, Largajolli, Anna, Hussain, Azher, Kleijn, Huub, Ait‐Oudhia, Sihem, Anton, Judith, Krishna Ananthula, Hari, Nussbaum, Jesse, La Rosa, Carmen, Gheyas, Ferdous
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431053/
https://www.ncbi.nlm.nih.gov/pubmed/37147897
http://dx.doi.org/10.1002/psp4.12978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431053/
https://www.ncbi.nlm.nih.gov/pubmed/37147897
http://dx.doi.org/10.1002/psp4.12978

Ejemplares similares